BioGenes GmbH, a medium-sized biotech company, specializing in ELISA development and production, is celebrating its 25-year anniversary. In 1992, the scientists Dr. Alexander Knoll and Dr. Sergej Ovodov set out with a vision to provide services and kits for the quality control of biotherapeutics. Over the course of the last 25 years, BioGenes’s vision has become a reality. BioGenes has grown from a small niche start-up firm providing antibody services to a worldwide leading provider of host cell protein (HCP) assays, customized ELISA development and analytical services.
Company founder and CEO Dr. Alexander Knoll remarked: "This is an incredible milestone for our company. The company has achieved this success through the hard work, passion, and dedication of our team members and our culture of customer service that exists throughout the entire organization. I’m proud to say that our teams consistently exceed client expectations by providing the most efficient, and proactive services to each and every project.”
"To this day BioGenes is still driven by the entrepreneurial spirit of our founders, which has enabled us to constantly expand our offering portfolio," said Dagmar Schwertner, Marketing & Sales Director, who has been with the company for 23 years. "In the fall of 2017, BioGenes will be launching a new product for immunogenicity testing.” As of today, BioGenes’ offerings include:
- Customized ELISA development
- Multi-product (platform) and specific HCP assays
- Generic HCP ELISAs (360-HCP assays for CHO cells and E.coli)
- Customized antibodies (incl. anti-idiotypic antibodies)
- Analytical services (2D DIGE, 2D Western blot, HCP coverage determination etc.)
In its 25 years, BioGenes has accomplished numerous projects with its customers. Find out more about BioGenes at www.BioGenes.de.
BioGenes GmbH specializes in highly sophisticated and customized antibody and immunoassay development and is an experienced and reliable partner for process development improvements in all areas of quality control, diagnostics and drug discovery. BioGenes is certified to meet the international requirements and regularities of quality assurance and animal welfare. The Company maintains long-term relationships with research institutes, universities and biotech and pharmaceutical companies, including eight of the ten largest pharmaceutical companies in the world. The company has been evaluated by a leading global accounting and auditing firm to be one of the leading companies in HCP assay development.